Company intelligence / Profile preview

Genuine Biotech

Ownership: Private
Development stage: Commercial

Overview

Genuine Biotech has received approval in China for Azvudine (July 2021) for COVID-19. The company has multiple programs in clinical development, including Doxitinib mesylate in Phase 1/2 for lung cancer, CL-197 in Phase 1 for HIV, and GEN-725 in Phase 1 for advanced solid tumors.

Therapeutic areas: GastroenterologyCardiovascularHematologyOncologyInfectious Diseases
Modalities: Small molecule drugsMonoclonal antibodiesADC (Antibody-Drug Conjugate)
Industry: Biotech

Drug pipeline

10 assets

azvudine

9 more assets in the full pipeline.

Request access →

Partnerships

Fosun PharmaFosun Foundation

Beyond the preview

Go deeper on Genuine Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genuine Biotech.

Explore the full profile